Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | SENIOR VICE PRESIDENT | April 27, 2021 | April 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 27, 2021 · Filed April 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 51,083 |
Reported balance
After 2021-04-27 transaction · row 1
1 source rowRow 1 · 2021-04-27 · Sale · Disposed 9,439 · Balance 51,083 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2021 Filed Apr 29, 2021 22:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,439 | $122.00 | $1,151,558.00 |
DisclosureSEC source: 0001415889-21-002194 · form4-04292021_030450.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,083 Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 23:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,113 | $120.61 | $134,238.93 |
DisclosureSEC source: 0001415889-21-001196 · form4-03022021_030350.xml · nonDerivative · entry 2 BIRD ROGER · CIK 0001635313 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,522 Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 23:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,999 | $121.58 | $972,518.42 |
DisclosureSEC source: 0001415889-21-001196 · form4-03022021_030350.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,635 Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 66,658 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000884 · form4-02232021_030214.xml · derivative · entry 2 BIRD ROGER · CIK 0001635313 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,658 Underlying: Common Shares · 66,658 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,219 on February 19, 2022, 22,219 on February 19, 2023, and 22,220 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,004 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000884 · form4-02232021_030214.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,634 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 21:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,290 | $108.73 | $683,929.31 |
DisclosureSEC source: 0001179110-20-009564 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,630 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.54 to $108.86, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 666 | $77.89 | $51,874.74 |
DisclosureSEC source: 0001179110-20-002908 · edgar.xml · nonDerivative · entry 2 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,920 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,736 | $79.19 | $612,613.84 |
DisclosureSEC source: 0001179110-20-002908 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,586 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 87,628 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002263 · edgar.xml · derivative · entry 2 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,628 Underlying: Common shares · 87,628 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,209 on February 21, 2021, 29,209 on February 21, 2022, and 29,210 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 14,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002263 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,322 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| July 26, 2019 Filed Jul 31, 2019 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 2,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-043011 · a4.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,947 Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 288 | $79.07 | $22,772.16 |
DisclosureSEC source: 0001179110-19-003862 · edgar.xml · nonDerivative · entry 3 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,807 Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $79.07 | $7,907.14 |
DisclosureSEC source: 0001179110-19-003862 · edgar.xml · nonDerivative · entry 2 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,095 Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,800 | $79.06 | $695,736.80 |
DisclosureSEC source: 0001179110-19-003862 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,195 Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,113 | $78.00 | $86,814.00 |
DisclosureSEC source: 0001179110-19-003107 · edgar.xml · nonDerivative · entry 2 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,995 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,087 | $77.23 | $547,329.01 |
DisclosureSEC source: 0001179110-19-003107 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,108 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 99,706 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002631 · edgar.xml · derivative · entry 2 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,706 Underlying: Common shares · 99,706 shares Expires 2029-02-21 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 33,235 on February 22, 2020, 33,235 on February 22, 2021, and 33,236 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,021 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002631 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,195 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.76 | $12,551.00 |
DisclosureSEC source: 0001179110-18-004164 · edgar.xml · nonDerivative · entry 3 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,174 Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.75 | $12,550.58 |
DisclosureSEC source: 0001179110-18-004164 · edgar.xml · nonDerivative · entry 2 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,374 Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,862 | $62.75 | $493,348.36 |
DisclosureSEC source: 0001179110-18-004164 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,574 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,545 | $58.80 | $90,847.55 |
DisclosureSEC source: 0001179110-18-003306 · edgar.xml · nonDerivative · entry 3 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,436 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $58.81 | $5,880.50 |
DisclosureSEC source: 0001179110-18-003306 · edgar.xml · nonDerivative · entry 2 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,981 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,487 | $60.55 | $332,237.85 |
DisclosureSEC source: 0001179110-18-003306 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,081 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 122,385 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002527 · edgar.xml · derivative · entry 2 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,385 Underlying: Common shares · 122,385 shares Expires 2028-02-15 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 40,795 on 02/16/2019, 40,795 on 02/16/2020, and 40,795 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 22,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002527 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,568 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,600 | $43.82 | $245,392.56 |
DisclosureSEC source: 0001179110-17-006291 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,313 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,601 | $45.02 | $72,069.02 |
DisclosureSEC source: 0001179110-17-003675 · edgar.xml · nonDerivative · entry 2 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,913 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,350 | $45.46 | $197,751.00 |
DisclosureSEC source: 0001179110-17-003675 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,514 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,873 | $0.00 Strike: $26.20 | $0.00 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · derivative · entry 16 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,873 shares Expires 2018-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 11,030 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · derivative · entry 15 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 11,030 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 167 | $45.05 | $7,522.52 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 13 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,864 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $45.04 | $4,504.10 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 12 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,031 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $45.04 | $18,016.00 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 11 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,131 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,500 | $45.04 | $67,552.50 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 10 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,531 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $45.03 | $4,503.10 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 9 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,031 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 700 | $45.03 | $31,521.00 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 8 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,131 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,936 | $45.02 | $447,318.72 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 7 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,831 Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,873 | $26.20 | $49,068.10 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 6 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 11,030 | $26.70 | $294,471.22 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 5 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $45.00 | $4,499.50 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 4 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,864 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 219 | $44.91 | $9,835.29 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 3 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,964 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 727 | $44.69 | $32,489.63 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 2 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,183 Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 92,032 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · derivative · entry 14 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,032 Underlying: Common shares · 92,032 shares Expires 2027-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,678 on 02/17/2018, 30,677 on 02/17/2019, and 30,677 on 02/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,910 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 22:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,910 | $39.52 | $75,483.20 |
DisclosureSEC source: 0001179110-16-020709 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,603 Read SEC document |
| February 21, 2016 Filed Feb 23, 2016 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 767 | $38.53 | $29,552.51 |
DisclosureSEC source: 0001179110-16-019898 · edgar.xml · nonDerivative · entry 2 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,513 Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 145,547 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-16-019898 · edgar.xml · derivative · entry 3 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,547 Underlying: Common shares · 145,547 shares Expires 2026-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 48,516 on 02/19/2017, 48,515 on 02/19/2018, and 48,516 on 02/19/2019. Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 16,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-019898 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,280 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2016 Filed Feb 17, 2016 22:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,131 | $37.13 | $41,994.03 |
DisclosureSEC source: 0001179110-16-019502 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,679 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.